# Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors

> **NCT04906473** · PHASE1 · UNKNOWN · sponsor: **Kunming Pharmaceuticals, Inc.** · enrollment: 109 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** KY100001

## Key facts

- **NCT ID:** NCT04906473
- **Lead sponsor:** Kunming Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-31
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 109 (ESTIMATED)
- **Last updated:** 2021-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906473, "Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04906473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*